Patents Assigned to Portola Pharmaceuticals, Inc.
  • Antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 9388401
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: July 12, 2016
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • Pyrazine kinase inhibitors
    Patent number: 9359308
    Abstract: Provided are pyrazine compounds of Formula (I) for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: June 7, 2016
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Yonghong Song, Qing Xu, Zhaozhong J. Jia, Brian Kane, Shawn M. Bauer, Anjali Pandey
  • Benzamides and nicotinamides as Syk modulators
    Patent number: 9359375
    Abstract: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: June 7, 2016
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Zhaozhong J. Jia, Yonghong Song, Qing Xu, Brian Kane, Shawn M. Bauer, Anjali Pandey
  • Compounds and methods for purification of serine proteases
    Patent number: 9200268
    Abstract: Disclosed herein are compounds, compositions, methods and kits for purifying a serine protease and serine proteases purified with the compounds, compositions and methods.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 1, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Anjali Pandey, Jack W. Rose
  • Inhibitors of protein kinases
    Patent number: 9139581
    Abstract: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: September 22, 2015
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Yonghong Song, Qing Xu, Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Anjali Pandey
  • Antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 9109046
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: August 18, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
  • Nicotinamides as JAK kinase modulators
    Patent number: 9102625
    Abstract: The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: August 11, 2015
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Shawn M. Bauer, Yonghong Song, Qing Xu, Jack W. Rose, Zhaozhong J. Jia, Brian Kane, Wolin Huang, Anjali Pandey, Mukund Mehrotra
  • Antidotes for factor XA inhibitors and methods of using the same
    Patent number: 9062298
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: June 23, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 9056106
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: June 16, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • 1,2,4-triazine-6-carboxamide kinase inhibitors
    Patent number: 9040530
    Abstract: Provided are triazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 26, 2015
    Assignee: PORTOLA PHARMACEUTICALS, INC.
    Inventors: Zhaozhong J. Jia, Brian Kane, Jack Rose, Shawn M. Bauer, Yonghong Song, Qing Xu, Anjali Pandey
  • Antidotes for factor XA inhibitors and methods of using the same
    Patent number: 9023796
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: May 5, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • Methods of synthesizing factor Xa inhibitors
    Patent number: 8987463
    Abstract: Described herein are novel methods of preparing a compound of Formula II or a pharmaceutically acceptable salt thereof. In some embodiments, the method is for preparing betrixaban or a pharmaceutically acceptable salt thereof. Also described are compositions comprising substantially pure betrixaban free base or salt thereof.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: March 24, 2015
    Assignees: Millennium Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc.
    Inventors: Anjali Pandey, Emilia P. T. Leitao, Jose Rato, Zhiguo Jake Song
  • Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
    Patent number: 8987285
    Abstract: The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral formulation of this novel crystalline form, its preparation and use thereof.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: March 24, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Ulrich Meier, Nicole Bieri, Dieter Becker, Julien Taillemite, Marie-Pierre Filliot, Tanja Meister
  • Inhibitors of syk and JAK protein kinases
    Patent number: 8952027
    Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: February 10, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Zhaozhong J. Jia, Chandrasekar Venkataramani, Wolin Huang, Mukund Mehrotra, Yonghong Song, Qing Xu, Shawn M. Bauer, Jack W. Rose, Brian Kane, Anjali Pandey
  • Combination therapy with a compound acting as a platelet ADP receptor inhibitor
    Patent number: 8946219
    Abstract: The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: February 3, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Pamela B. Conley, Patrick Andre, Uma Sinha
  • Crystalline forms of a factor Xa inhibitor
    Patent number: 8946269
    Abstract: Provided herein are crystalline forms of a maleate salt of betrixaban, compositions and methods of preparation or use thereof.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: February 3, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Vincent R. Capodanno, Liam Corcoran, Michael McNevin, Itzia Zoraida Arroyo, Robert M. Wenslow, Richard G. Ball, Eric L. Margelefsky, Timothy K. Maher, Anjali Pandey
  • Inhibitors of protein kinases
    Patent number: 8937070
    Abstract: The present invention is directed to methods of inhibiting syk and/or JAK kinase activity, methods of inhibiting platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma with compounds of the formula: and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: January 20, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Shawn M. Bauer, Anjali Pandey
  • Antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 8889129
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: November 18, 2014
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • Substituted pyrazine-2-carboxamide kinase inhibitors
    Patent number: 8877760
    Abstract: Provided are substituted pyrazine-2-carboxamide compounds of Formula I: useful for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: November 4, 2014
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Yonghong Song, Anjali Pandey
  • SELECTIVE KINASE INHIBITORS
    Publication number: 20140323418
    Abstract: Provided are pyrimidine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.
    Type: Application
    Filed: November 23, 2012
    Publication date: October 30, 2014
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Zhaozhong J. Jia, Brian Kane, Qing Xu, Shawn M. Bauer, Yonghong Song, Anjali Pandey, Ryan Dick